Sutro Biopharma Inc (NASDAQ:STRO) currently has a daily average trading volume of 1.31M but it saw 1671024 shares traded in last market. With a market cap of 68.76M USD, the company’s current market price of $0.82 came falling about -8.40 while comparing to the previous closing price of $0.90. In past 52 weeks, the stock remained buoying in the range of price level as high as $6.13 and as low as $0.76. In the recent trading on the day, stock has struck highest price mark of $0.8208 while lowest mark touched by it was $0.965.
Taking a look at 20-day trading activity of Sutro Biopharma Inc (STRO) gives us an average price of $1.3787, while its current price level is -86.61% below from 52-week high level whereas it is 7.70% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.6926 while that of 200 days or SMA-200 reads an average of $3.0249. A closer look into the stock’s movement over the week reveals that its volatility is standing at 19.43% during that period while stretching the period over a month that decreases to 11.44%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 26.15 which implies that the stock is in oversold territory.
Wedbush downgraded its recommendation for the stock as a “Neutral” from “Outperform” on March 14, 2025 while assigning a price target range of $8-$2.
Over the week, STRO’s stock price is moving -38.75% down while it is -56.11% when we observe its performance for the past one month. Year-to-date it is -55.39% down and over the past year, the stock is showing a downside performance of -80.03%.
The company is expected to be releasing its next quarterly report on 2025-Mar-12, for which analysts forecasted an EPS of 0 while estimate for next year EPS is -2.48. In next quarter, company is expected to be making quarterly sales of $11.54M as analysts are expecting the sales for current fiscal year at $47.14M and seeing the company making $51.77M in sales next year. Moreover, analysts are in estimates of $11.61M for current-quarter revenue.
Currently, Sutro Biopharma Inc’s total number of outstanding shares is 82.53M with 4.21% of that held by the insiders while 73.99% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -94.35% and return on equity (ROE) at -234.19%. Stock’s beta reads 1.62. Stock has a price to book (P/B) ratio of 1.52 while price to sale or P/S ratio amounts to 1.11. Its return on asset (ROA) is -53.02% on average.
